Sanchit Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sanchit Sharma has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ashish Agarwal
Department of Gastroenterology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
2 shared publications - Dhiraj Tripathi
Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
2 shared publications - Rajesh Panwar
Department of Gastrointestinal Surgery, All India Institute of Medical Sciences, New Delhi, India
2 shared publications Anoop Saraya
Gastroenterology and Human Nutrition Unit, AIIMS, New Delhi, India
1 shared publication- Anoop Saraya
Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India
1 shared publication - Arti Gupta
Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India
1 shared publication
Latest Publications
- 19 February 2026
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 16 (2) , 103505
Therapies for Prevention of Gastric Variceal Bleeding: Do We Have a Winner?
- 19 February 2026
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 16 (2) , 103505
Therapies for Prevention of Gastric Variceal Bleeding: Do We Have a Winner?
- 7 January 2026
- Published by BMJ in Frontline Gastroenterology
Long-term outcomes in patients with porto-sinusoidal vascular disorder: a single-centre 10-year follow-up study
Objective: Porto-sinusoidal vascular disorder (PSVD) is a recently described nomenclature with limited data on long-term outcomes. We evaluated the outcomes in a cohort of PSVD patients and determined whether these differed from patients classified as per the previous idiopathic non-cirrhotic portal hypertension (INCPH) criteria. Design: In this single-centre retrospective study, baseline characteristics and liver-related outcomes were evaluated in patients with PSVD. The prognostic performance of the nomogram from the Vascular Liver Disease Group (VALDIG) consortium was assessed. Outcomes were compared in patients categorised as PSVD (PSVD+/INCPH-) as per new nomenclature with those who, in addition, fulfilled previous INCPH (PSVD+/INCPH+) criteria. Results: Eighty patients were included (mean age: 44 years and 38% females). History of PH-related complications was present in 36 (45%) patients at diagnosis. Median follow-up duration from diagnosis was 78 (IQR: 27–132) months. The cumulative 5-year and 10-year probability of liver-related events was as follows: PH-related bleed (15.4% and 21.8%), new onset/worsening ascites (21.6% and 35%), splanchnic vein thrombosis (15.9% and 21%) and transplant-free survival (70.5% and 60.72%), respectively. The VALDIG nomogram showed good discrimination (optimism-corrected C-statistic: 0.769) but over-estimated survival. Patients classified as PSVD+/INCPH+ (n=26) were younger (mean age: 39 vs 48 years, p=0.013), had a higher prevalence of varices (92% vs 59%, p=0.027), but had similar outcomes (10-year survival: 63.5% vs 59.3%; HR, 0.76 (95% CI 0.33 to 1.75), p=0.52) compared with the PSVD+/INCPH− group (n=54). Conclusion: This study describes long-term outcomes in PSVD from a quaternary centre. VALDIG prognostic nomogram may need recalibration through further external validation. Outcomes were similar irrespective of the nomenclature used to define this cohort.
- 7 January 2026
- Published by BMJ in Frontline Gastroenterology
Long-term outcomes in patients with porto-sinusoidal vascular disorder: a single-centre 10-year follow-up study
Objective: Porto-sinusoidal vascular disorder (PSVD) is a recently described nomenclature with limited data on long-term outcomes. We evaluated the outcomes in a cohort of PSVD patients and determined whether these differed from patients classified as per the previous idiopathic non-cirrhotic portal hypertension (INCPH) criteria. Design: In this single-centre retrospective study, baseline characteristics and liver-related outcomes were evaluated in patients with PSVD. The prognostic performance of the nomogram from the Vascular Liver Disease Group (VALDIG) consortium was assessed. Outcomes were compared in patients categorised as PSVD (PSVD+/INCPH-) as per new nomenclature with those who, in addition, fulfilled previous INCPH (PSVD+/INCPH+) criteria. Results: Eighty patients were included (mean age: 44 years and 38% females). History of PH-related complications was present in 36 (45%) patients at diagnosis. Median follow-up duration from diagnosis was 78 (IQR: 27–132) months. The cumulative 5-year and 10-year probability of liver-related events was as follows: PH-related bleed (15.4% and 21.8%), new onset/worsening ascites (21.6% and 35%), splanchnic vein thrombosis (15.9% and 21%) and transplant-free survival (70.5% and 60.72%), respectively. The VALDIG nomogram showed good discrimination (optimism-corrected C-statistic: 0.769) but over-estimated survival. Patients classified as PSVD+/INCPH+ (n=26) were younger (mean age: 39 vs 48 years, p=0.013), had a higher prevalence of varices (92% vs 59%, p=0.027), but had similar outcomes (10-year survival: 63.5% vs 59.3%; HR, 0.76 (95% CI 0.33 to 1.75), p=0.52) compared with the PSVD+/INCPH− group (n=54). Conclusion: This study describes long-term outcomes in PSVD from a quaternary centre. VALDIG prognostic nomogram may need recalibration through further external validation. Outcomes were similar irrespective of the nomenclature used to define this cohort.
- Open Access
- 30 July 2021
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 19 (3) , 291-300
Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
Background/Aims: Exclusive enteral nutrition (EEN), an established modality for pediatric Crohn’s disease (CD) is seldomly utilized in adults. The present study reports the outcome of EEN in adult CD patients at a tertiary care hospital in India.Methods: This was a retrospective analysis of CD patients who received EEN as a sole modality/adjunct to other treatment. The primary and secondary outcomes changed in Crohn’s Disease Activity Index (CDAI), and clinical response (decline in CDAI > 70), respectively, at 4 and 8 weeks. Subgroup analysis evaluated response across different phenotypes, EEN formulations and prior treatment. Linear mixed effect model was created to assess the predictors of EEN response.Results: Thirty-one CD patients received EEN over median duration of 4 weeks (range, 2–6 weeks). CDAI showed a significant improvement post EEN at 4 (baseline 290 [260–320] vs. 240 [180–280], P= 0.001) and 8 weeks (baseline 290 [260–320] vs. 186 [160–240], P= 0.001), respectively. The cumulative clinical response rates at 4 and 8 weeks were 37.3% and 80.4% respectively. The clinical response rates at 8 weeks across B1 (n = 4), B2 (n = 18) and B3 (n = 9) phenotypes were 50%, 78.8% and 100% respectively (log-rank test, P= 0.093). The response rates at 8 weeks with polymeric (n = 8) and semi-elemental diet (n = 23) were 75% and 82.6%% respectively (log-rank test, P= 0.49). Baseline CDAI (odds ratio, 1.008; 95% confidence interval, 1.002–1.017; P= 0.046) predicted response to EEN.Conclusions: EEN was effective in inducing clinical response across different phenotypes of CD. Baseline disease activity remained the most important predictor of clinical response to EEN.
- 30 July 2021
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 19 (3) , 291-300
Open AccessEfficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
Background/Aims: Exclusive enteral nutrition (EEN), an established modality for pediatric Crohn’s disease (CD) is seldomly utilized in adults. The present study reports the outcome of EEN in adult CD patients at a tertiary care hospital in India.Methods: This was a retrospective analysis of CD patients who received EEN as a sole modality/adjunct to other treatment. The primary and secondary outcomes changed in Crohn’s Disease Activity Index (CDAI), and clinical response (decline in CDAI > 70), respectively, at 4 and 8 weeks. Subgroup analysis evaluated response across different phenotypes, EEN formulations and prior treatment. Linear mixed effect model was created to assess the predictors of EEN response.Results: Thirty-one CD patients received EEN over median duration of 4 weeks (range, 2–6 weeks). CDAI showed a significant improvement post EEN at 4 (baseline 290 [260–320] vs. 240 [180–280], P= 0.001) and 8 weeks (baseline 290 [260–320] vs. 186 [160–240], P= 0.001), respectively. The cumulative clinical response rates at 4 and 8 weeks were 37.3% and 80.4% respectively. The clinical response rates at 8 weeks across B1 (n = 4), B2 (n = 18) and B3 (n = 9) phenotypes were 50%, 78.8% and 100% respectively (log-rank test, P= 0.093). The response rates at 8 weeks with polymeric (n = 8) and semi-elemental diet (n = 23) were 75% and 82.6%% respectively (log-rank test, P= 0.49). Baseline CDAI (odds ratio, 1.008; 95% confidence interval, 1.002–1.017; P= 0.046) predicted response to EEN.Conclusions: EEN was effective in inducing clinical response across different phenotypes of CD. Baseline disease activity remained the most important predictor of clinical response to EEN.
- Open Access
- 14 May 2021
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Special Considerations in the Management of Autoimmune Hepatitis in COVID-19 Hotspots: A Review
The ongoing coronavirus disease-2019 (COVID-19) pandemic has necessitated special considerations in the management of diseases. The way presence of pre-existing diseases or treatment for it predisposes to, alters course of, and changes the management of COVID-19, is of relevance and is being extensively studied. Autoimmune hepatitis (AIH) is unique in that it is an autoimmune disease mandating treatment with immunosuppressive drugs, as well as a liver disease with potential for varying degrees of underlying fibrosis. The use of immunosuppressive drugs could alter the risk of acquiring COVID-19, the clinical course and severity of COVID-19 and the degree of underlying liver fibrosis could alter the clinical outcomes of patients with COVID-19. In this review, we try to summarize key areas relevant in understanding and improving the clinical care of patients with AIH in the current pandemic. Special considerations required in the management of patients with AIH in COVID-19 hotspots have been outlined based on the current evidence.
- 14 May 2021
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000) , 000
Open AccessSpecial Considerations in the Management of Autoimmune Hepatitis in COVID-19 Hotspots: A Review
The ongoing coronavirus disease-2019 (COVID-19) pandemic has necessitated special considerations in the management of diseases. The way presence of pre-existing diseases or treatment for it predisposes to, alters course of, and changes the management of COVID-19, is of relevance and is being extensively studied. Autoimmune hepatitis (AIH) is unique in that it is an autoimmune disease mandating treatment with immunosuppressive drugs, as well as a liver disease with potential for varying degrees of underlying fibrosis. The use of immunosuppressive drugs could alter the risk of acquiring COVID-19, the clinical course and severity of COVID-19 and the degree of underlying liver fibrosis could alter the clinical outcomes of patients with COVID-19. In this review, we try to summarize key areas relevant in understanding and improving the clinical care of patients with AIH in the current pandemic. Special considerations required in the management of patients with AIH in COVID-19 hotspots have been outlined based on the current evidence.
- 5 February 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (2) , e236372
Case of cholestatic jaundice associated with papillary carcinoma of thyroid: a multidisciplinary challenge
The report describes a patient with cholestatic jaundice who had incidentally detected parathyroid hormone-independent hypercalcaemia. The differential diagnosis for this presentation includes systemic granulomatous and infiltrative disorders, drug-induced liver injury and malignancy. As the initial investigations were non-contributory towards the aetiology, she was given steroids and later plasma exchange for symptomatic treatment. The differentials were revised again in view of no clinical and biochemical response. A repeat fine-needle aspiration cytology of the thyroid nodule (seen on positron emission tomography/CT) revealed papillary carcinoma of the thyroid. The patient underwent total thyroidectomy. There was a complete normalisation of liver function tests and serum calcium, and resolution of pruritus 3 months post surgery. She was retrospectively diagnosed as a case of papillary carcinoma of the thyroid with paraneoplastic manifestations—hypercalcaemia and cholestatic jaundice—which got resolved with treatment of the primary tumour.
- 5 February 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (2) , e236372
Case of cholestatic jaundice associated with papillary carcinoma of thyroid: a multidisciplinary challenge
The report describes a patient with cholestatic jaundice who had incidentally detected parathyroid hormone-independent hypercalcaemia. The differential diagnosis for this presentation includes systemic granulomatous and infiltrative disorders, drug-induced liver injury and malignancy. As the initial investigations were non-contributory towards the aetiology, she was given steroids and later plasma exchange for symptomatic treatment. The differentials were revised again in view of no clinical and biochemical response. A repeat fine-needle aspiration cytology of the thyroid nodule (seen on positron emission tomography/CT) revealed papillary carcinoma of the thyroid. The patient underwent total thyroidectomy. There was a complete normalisation of liver function tests and serum calcium, and resolution of pruritus 3 months post surgery. She was retrospectively diagnosed as a case of papillary carcinoma of the thyroid with paraneoplastic manifestations—hypercalcaemia and cholestatic jaundice—which got resolved with treatment of the primary tumour.
- Open Access
- 28 December 2020
- Published by Georg Thieme Verlag KG in Journal of Digestive Endoscopy
- Vol. 13 (01) , 058-060
Successful Endoscopic Removal of a Transmural Internally Migrating Gossypiboma
An accidentally retained sponge inside the body of a patient (gossypiboma) is a rare and serious adverse event after a surgical procedure with serious medicolegal implications and complications. It is commonly associated with abdominal surgeries with cholecystectomy most commonly implicated. Whorl-like appearance or mottled translucencies and radiopaque marker on imaging is diagnostic. Transmural migration into a hollow viscous has been infrequently reported. The preferred approach for the removal of gossypiboma is surgery. However, in cases of complete transmural migration, endoscopic removal remains a viable option.
- 28 December 2020
- Published by Georg Thieme Verlag KG in Journal of Digestive Endoscopy
- Vol. 13 (01) , 058-060
Open AccessSuccessful Endoscopic Removal of a Transmural Internally Migrating Gossypiboma
An accidentally retained sponge inside the body of a patient (gossypiboma) is a rare and serious adverse event after a surgical procedure with serious medicolegal implications and complications. It is commonly associated with abdominal surgeries with cholecystectomy most commonly implicated. Whorl-like appearance or mottled translucencies and radiopaque marker on imaging is diagnostic. Transmural migration into a hollow viscous has been infrequently reported. The preferred approach for the removal of gossypiboma is surgery. However, in cases of complete transmural migration, endoscopic removal remains a viable option.